corresponding to Human IKB alpha.
This product is a recombinant rabbit monoclonal antibody.
Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Our Abpromise guarantee covers the use of ab92700 in the following tested applications.
|WB||1/500 - 1/10000. Predicted molecular weight: 36 kDa.|
|IP||1/10 - 1/100.|
Blocking/Diluting buffer and concentration 5% NFDM/TBST
ab92700 at 1/20 dilution immunoprecipitating IKB alpha (phospho S32) in HeLa (human cervix adenocarcinoma) treated with 20ng/mL TNF-alpha for 60 minutes, whole cell lysate, observed at 36 kDa (lanes 1 and 2).
Lane 1 (input): HeLa treated with 20ng/mL TNF-alpha for 60 minutes, whole cell lysate, 10μg.
Lane 2 (+): ab92700 + HeLa treated with 20ng/mL TNF-alpha for 60 minutes, whole cell lysate.
Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab92700 in HeLa treated with 20ng/mL TNF-alpha for 60 minutes, whole cell lysate.
For western blotting, ab92700 at 1/200 dilution followed by ab131366 VeriBlot for IP (HRP) at 1/1000 as the secondary antibody.
Blocking/Diluting buffer and concentration: 5% NFDM/TBST.
Dot blot analysis of IKB alpha (phospho S32) phospho peptide (Lane 1) and IKB alpha non-phospho peptide (Lane 2) labeling IKB alpha (phospho S32) with ab92700 at a dilution of 1/1000. ab97051 (Peroxidase conjugated goat anti-rabbit IgG) (H+L) at 1/10000 was used as the secondary antibody.
Blocking and diluting buffer: 5% NFDM/TBST.
Exposure time: 3 minutes.